Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone
| Autor: | Ritesh Patil, Jarrod P. Holmes, Sathibalan Ponniah, M. G. Carmichael, George E. Peoples, Guy T. Clifton, Nathan M. Shumway, Elizabeth A. Mittendorf, Alan K. Sears, D. C. Van Echo |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty biology business.industry medicine.medical_treatment Active immunization medicine.disease HER2/neu Vaccination Breast cancer Trastuzumab Internal medicine Immunology medicine Peptide vaccine biology.protein Cytotoxic T cell skin and connective tissue diseases business Adjuvant medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 29:564-564 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2011.29.15_suppl.564 |
| Popis: | 564 Background: We are conducting multiple, prospective, phase II trials evaluating different HER-2/neu(HER2) peptide vaccines in the adjuvant setting to prevent breast cancer (BrCa) recurrence. E75 (HER2: 369-377) and another vaccine (X) are HLA-A2/3+-restricted peptides capable of stimulating CD8+ cytotoxic T cells with anti-HER2 tumor activity. Trastuzumab (Tz), a recombinant monoclonal anti-HER2 antibody, has been shown to reduce BrCa recurrence by 50%. We examined the sequential use of Tz and a CD8 T cell-eliciting vaccine to compare the efficacy of sequential passive and active immunization to passive immunotherapy alone. Methods: We examined patients from our E75 and vaccine X clinical trials. HLA-A2/3+ node positive or high-risk node negative BrCa patients with any level of HER2 expression, disease-free after standard treatments were vaccinated with E75 or X+GM-CSF (immunoadjuvant) vs. nothing (E75 trial) or GM-CSF alone (X trial). Vaccinations were given as 6 monthly intradermal inoculations. Pat... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|